Voretigene neparvovec
| Gene therapy | |
|---|---|
| Target gene | RPE65 |
| Vector | Adeno-associated virus serotype 2 |
| Nucleic acid type | DNA |
| Clinical data | |
| Trade names | Luxturna |
| Other names | voretigene neparvovec-rzyl |
| AHFS/Drugs.com | Professional Drug Facts |
| License data | |
| Pregnancy category |
|
| Routes of administration |
Subretinal injection |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
| DrugBank | |
| UNII | |
| KEGG | |
Voretigene neparvovec, sold under the brand name Luxturna, is a gene therapy medication for the treatment of Leber congenital amaurosis.
Leber's congenital amaurosis, or biallelic RPE65-mediated inherited retinal disease, is an inherited disorder causing progressive blindness. Voretigene is the first treatment available for this condition. The gene therapy is not a cure for the condition, but substantially improves vision in those treated. It is given as a subretinal injection.
Voretigene neparvovec was approved for medical use in the United States in December 2017,Australia in August 2020 and in Canada, in October 2020. It is the first in vivo gene therapy approved by the US Food and Drug Administration (FDA).
Medical uses
Voretigene neparvovec is indicated for the treatment of people with vision loss due to inherited retinal dystrophy caused by confirmed biallelic RPE65 mutations and who have sufficient viable retinal cells.
Chemistry and production
Voretigene neparvovec is an AAV2 vector containing human RPE65 cDNA with a modified Kozak sequence. The virus is grown in HEK 293 cells and purified for administration.
History
It was developed by Spark Therapeutics and Children's Hospital of Philadelphia.
It was granted orphan drug designation for Leber congenital amaurosis and retinitis pigmentosa. A biologics license application was submitted to the US Food and Drug Administration (FDA) in July 2017 with Priority Review.Phase III clinical trial results were published in August 2017. On 12 October 2017, a key advisory panel to the FDA, composed of 16 experts, unanimously recommended approval of the treatment. The FDA approved the drug on in December 2017. With the approval, Spark Therapeutics received a pediatric disease priority review voucher.
The first commercial sale of voretigene neparvovec, which was also the first sale of any gene therapy product in the United States, occurred in March 2018. The price of the treatment at the time was announced as being $425,000 per eye.
Further reading
- Ledford H (October 2017). "FDA advisers back gene therapy for rare form of blindness". Nature. 550 (7676): 314. Bibcode:2017Natur.550..314L. doi:10.1038/nature.2017.22819. PMID 29052639.
- Wilson JM (March 2018). "Interview with Jean Bennett, MD, PhD". Human Gene Therapy. Clinical Development. 29 (1): 7–9. doi:10.1089/humc.2018.29032.int. PMID 29641279.
- Ameri H (March 2018). "Prospect of retinal gene therapy following commercialization of voretigene neparvovec-rzyl for retinal dystrophy mediated by RPE65 mutation". Journal of Current Ophthalmology. 30 (1): 1–2. doi:10.1016/j.joco.2018.01.006. PMC 5859497. PMID 29564403.
- Russell S, Bennett J, Maguire AM, High KA (2018). "Voretigene neparvovec-rzyl for the treatment of biallelic RPE65 mutation–associated retinal dystrophy". Expert Opinion on Orphan Drugs. 6 (8): 457–464. doi:10.1080/21678707.2018.1508340. S2CID 81437112.
- Bakall B, Hariprasad SM, Klein KA (July 2018). "Emerging Gene Therapy Treatments for Inherited Retinal Diseases". Ophthalmic Surgery, Lasers & Imaging Retina. 49 (7): 472–478. doi:10.3928/23258160-20180628-02. PMID 30021033.
- "Drug and Device News". P & T. 43 (2): 74–104. February 2018. PMC 5768294. PMID 29386862.
External links
- "Voretigene neparvovec". Drug Information Portal. U.S. National Library of Medicine.